Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
γ-Aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the central nervous system (CNS). It exerts its rapid inhibitory action mostly through GABA A receptors, which are targets for benzodiazepines, barbiturates, neuroactive steroids and distinct anticonvulsive agents. There is considerable evidence that dysfunction of GABA A receptors or dysregulation of GABA concentrations in the CNS (or both) plays an important role in the pathophysiology of panic disorder. Currently, benzodiazepines are the only drugs directly targeting the GABA A receptors that are approved for the treatment of anxiety disorders. Because of their well-known anxiolytic effects, they are widely used in this setting, but side effects limit their use in long-term treatment. The question of whether drugs that selectively increase GABA concentrations in the CNS could improve symptoms of anxiety has been discussed. Recent investigations by our group have demonstrated that enhancement of endogenous GABA (through blockade of GABA transaminase by vigabatrin or through inhibition of GABA transporters by tiagabine) exerts anxiolytic effects on experimentally induced panic. Our studies in healthy volunteers have shown that both compounds lead to a significant reduction in panic symptoms elicited by cholecystokinin-tetrapeptide. Moreover, benzodiazepine-like effects on the activity of the hypothalamic–pituitary–adrenal axis have been observed in association with vigabatrin treatment. Small open studies in patients with panic disorder also showed an improvement in panic and anxiety with both compounds. This review summarizes our recent research on the effects of selective GABAergic treatment in experimentally induced panic and outlines the possible role of compounds targeting the GABA binding site of the GABA A–benzodiazepine receptor for the treatment of panic and anxiety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“Whereas sedation, anterograde amnesia and some anticonvulsant properties are mediated by the α1 subunit of the GABAA receptor, anxiolysis is mediated by the α2 subunit.(24) The presence of a γ subunit is required for benzodiazepine receptor binding.”
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties
Rupprecht, R. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00064-1 · Cited by 427
Self-citationNutt, D. J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220033004 · Cited by 272
Goddard, A. W., Mason, G. F., Almai, A., Rothman, D. L., Behar, K. L., Petroff, O. A. C., Charney, D. S., & Krystal, J. H. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.556 · Cited by 255
Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240
Cited by
Role of GABA in anxiety and depression
Kalueff, A. V., & Nutt, D. J. (2007) · Depression and Anxiety · doi:10.1002/da.20262 · Cited by 534
Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., Cinosi, E., Davies, S., Domschke, K., Fineberg, N., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1190867 · Cited by 347
“For both compounds, anxiolytic action has been suggested through clinical studies and studies using pharmacological panic induction with CCK-4 (for a review, see Zwanzger & Rupprecht, 2005).”
BackgroundSelf-citationTranslocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects
Rupprecht, R., Rammes, G., Eser, D., Baghai, T. C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H. O., Chaperon, F., et al. (2009) · Science · doi:10.1126/science.1175055 · Cited by 328
Self-citationWho is at risk for ongoing dizziness and psychological strain after a vestibular disorder?
Best, C., Tschan, R., Eckhardt-Henn, A., & Dieterich, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.09.034 · Cited by 142
Domschke, K., Tidow, N., Schrempf, M., Schwarte, K., Klauke, B., Reif, A., Kersting, A., Arolt, V., Zwanzger, P., & Deckert, J. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.014 · Cited by 87
“…system has been proposed as a major neurobiological pathomechanism of anxiety (Domschke and Zwanzger, 2008; Nemeroff, 2003; Roy-Byrne, 2005; Zwanzger and Rupprecht, 2005): patients with anxiety disorders and panic disorder in particular have e.g. been reported to exhibit significantly…”
BackgroundSelf-citationEvidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
“…al. 2004; Dannon et al. 2002; Seedat et al. 2003; Versiani et al. 2002), GABAergic treatment including vigabatrin and tiagabine (Pande et al. 2000; Zwanzger & Rupprecht, 2005 ; Zwanzger et al. 2009a), the reversible MAOI moclobemide (Kruger & Dahl, 1999; Loerch et al. 1999; Ross et al. 2010;…”
BackgroundAngsterkrankungen und Therapieresistenz: Klinische Empfehlungen und Perspektiven
Zwanzger, P., & Diemer, J. (2019) · Nervenheilkunde · doi:10.1055/a-0961-2589 · Cited by 2
Self-citation
Metadata
- Authors
- Zwanzger, P., & Rupprecht, R.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2005-05
- Volume
- 30
- Issue
- 3
- Pages
- 167-175
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W2139938825
- Cited by
- 86
- References
- 6
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.